Fusion proteins created by chromosomal abnormalities are key components of mesenchymal cancer development. The most common chromosomal translocation in liposarcomas, t(12;16)(q13;p11), creates the FUS ± CHOP fusion gene. In the past, we generated FUS ± CHOP and CHOP transgenic mice and have shown that while FUS ± CHOP transgenic develop liposarcomas, mice expressing CHOP, which lacks the FUS domain, display essentially normal white adipose tissue (WAT) development, suggesting that the FUS domain of FUS ± CHOP plays a speci®c and critical role in the pathogenesis of liposarcoma. To test the signi®cance of FUS and CHOP domain interactions within a living mouse, we generated mice expressing the FUS domain and crossed them with CHOP-transgenic mice to generate double-transgenic FUSxCHOP animals. Here we report that expression of the FUS domain restores liposarcoma development in CHOP-transgenic mice. Our results provide genetic evidence that FUS and CHOP domains function in trans for the mutual restoration of liposarcoma. These results identify a new mechanism of tumor-associated fusion genes and might have impact beyond myxoid liposarcoma.
Introduction
Liposarcoma is the most common soft tissue malignancy in adults accounting for at least 20% of all sarcomas in this age group (Chang et al., 1989; Mack, 1995) . The myxoid/round cell liposarcomas exhibited the characteristic t(12;16)(q13;p11) translocation (Knight et al., 1995) . The molecular characterization of this translocation revealed a fusion between the CHOP gene and a gene called TLS/FUS (Crozat et al., 1993; Rabbitts et al., 1993) , resulting in the RNAbinding domain of TLS/FUS being replaced by the basic leucine zipper domain of CHOP, which confers the ability to form protein dimers (Ron and Habener, 1992; Crozat et al., 1993) . The TLS/FUS gene has also been shown to fuse with the gene for Ets-like protein ERG as a result of the translocation t(16;21)(p11;q22) in some patients with acute nonlymphoblastic leukemia (Shimizu et al., 1993; Ichikawa et al., 1994; Panagopoulos et al., 1994 Panagopoulos et al., , 1995 . The portion of TLS/FUS that is present in the TLS/FUS ± CHOP and FUS ± ERG fusion proteins is similar and this part has been shown to be an autonomous transcriptional activation domain (Prasad et al., 1994 ; SaÂ nchez-GarcõÂ a and Rabbitts, 1994; Zinszner et al., 1994) . In the FUS ± CHOP fusion, transcriptional activation is therefore speci®cally conferred on the chimeric protein by the FUS segment after the translocation event (SaÂ nchezGarcõÂ a and Rabbitts, 1994) . In vitro, the transforming eects of FUS ± CHOP have been demonstrated in ®broblasts (PeÂ rez-Losada et al., 2000a), but curiously not in 3T3 ± L1 cells under conditions expected to yield oncogenic eects (Zinszner et al., 1994) , suggesting that the function of FUS ± CHOP is in¯uenced by the cell environment in vitro. In vivo, mice expressing FUS ± CHOP develop liposarcomas (PeÂ rez-Losada et al., 2000a) . Whereas interference with the normal process of dierentiation may contribute to the oncogenic potential of FUS ± CHOP fusion protein, it is a property that they share with the nontransforming germline CHOP gene product (Zinszner et al., 1994; Batchvarova et al., 1995) . CHOP expression is tightly regulated. Under normal conditions the gene is repressed, and CHOP mRNA and protein are absent from cells (Fornace et al., 1989; Price and Calderwood, 1992; Carlson et al., 1993; Wang et al., 1996) . In contrast with CHOP, FUS is a constitutively activated gene (Aman et al., 1996) . These observations support a model whereby the FUS ± CHOP fusion gene repre- 
Results

Generation of transgenic mice expressing an altered form of FUS ± CHOP protein lacking the CHOP domain
We previously developed a mouse model of liposarcoma by expressing FUS ± CHOP from the elongation factor 1a (EF-1a) promoter in murine mesenchymal stem cells (PeÂ rez-Losada et al., 2000b) . In order to understand in vivo the role of FUS ± CHOP in the pathogenesis of liposarcoma, we have also generated transgenic mice expressing two altered forms of the FUS ± CHOP protein (PeÂ rez-Losada et al., 2000a) . The ®rst truncated protein (CHOP) which lacks the FUS domain did not aect WAT development in vivo. The second altered form of FUS ± CHOP, created by the in frame fusion of the FUS domain to the carboxy end of CHOP (CHOP ± FUS), induced liposarcomas in transgenic mice indicating that the FUS domain of FUS ± CHOP plays a speci®c and critical role in the pathogenesis of liposarcoma (PeÂ rez-Losada et al., 2000b) . To test the signi®cance of FUS and CHOP domain interactions within a living mouse, we have now generated mice expressing the FUS domain, a truncated FUS ± CHOP protein lacking the CHOP domain, to investigate the contribution of the FUS domain to the genesis of liposarcoma in vivo ( Figure  1a) . In vitro this truncated protein (FUS) is able to activate transcription (Prasad et al., 1994; SaÂ nchezGarcõÂ a and Rabbitts, 1994; Zinszner et al., 1994) .
In order to examine the direct consequences of FUS expression in vivo we follow the same strategy than we previously used for FUS ± CHOP (PeÂ rez-Losada et al., 2000a). Therefore, FUS cDNA was cloned downstream from the EF-1a promoter (EF ± FUS) to direct expression to all tissues ( Figure 1b ) and injected into C57BL/ 6xCBA fertilized eggs. Tissue expression of the EF ± FUS transgene was demonstrated by Western blot analysis with an 9E10 monoclonal antibody ( Figure 1c ).
WAT development is normal in EF-FUS transgenic mice
Cohorts of transgenic mice were generated to analyse the eect of the FUS gene. FUS transgenic mice developed healthy, were fertile and none of the FUS transgenic mice developed liposarcomas in up to 24 months of observation. This result is similar to CHOP transgenic mice (PeÂ rez-Losada et al., 2000b) and contrasts with our observations in the FUS ± CHOP transgenic mice which develop liposarcomas (PeÂ rezLosada et al., 2000a). Although liposarcomas did not develop in the FUS transgenic mice, we investigated whether the FUS protein altered white adipose tissue (WAT) development in these mice. The histopathological analyses of the white adipose depots in FUS transgenic mice did not evidence any pathological change within the terminally dierentiated adipocytes (Figure 2 ). On the contrary, FUS transgenic mice had a normal architecture of the tissue and we did not observe any shift in the WAT toward immature in the FUS transgenic mice.
Double-transgenic FUSxCHOP mice develop liposarcomas
We next investigated the signi®cance of FUS and CHOP domain interactions within a living mouse and crossed mice expressing the FUS domain with CHOPtransgenic mice (PeÂ rez-Losada et al., 2000b) to generate double-transgenic FUSxCHOP animals (Figure 1c) . Uniformly, male and female double-transgenic FUSxCHOP animals showed the same symptoms beginning as early as 8 ± 12 weeks of age with increasing signs over time leading to death by 12 months of age. At the time of autopsy, these animals had developed palpable masses involving the adipose tissues, which, upon dissection, revealed white adipose pads 4 ± 100-fold normal size. All these animals had visible masses as early as 8 ± 10 weeks. In addition, some animals never developed palpable masses but showed microscopic tumor upon dissection when they were sacri®ed at 12 weeks of age. This examination is consistent with adipose tissue disease. However, no tumors of other tissues were found in these doubletransgenic FUSxCHOP animals, despite widespread activity of the EF-1a promoter. Although we did not detect the presence of FUS ± CHOP protein in our double-transgenic FUSxCHOP animals (Figure 1c) , the possibility of recombination of FUS and CHOP resulting in expression of fused FUS ± CHOP sequences in the double-transgenic FUSxCHOP animals was ruled out by PCR with FUS forward and CHOP reverse primers (data not shown).
We next de®ned the adipose tissue disease generated in the double-transgenic FUSxCHOP animals. Detailed analysis of the tumor cells established the diagnosis as malignant liposarcomas.
Haematoxilin/Eosin staining showed that the tumor cells had an adipoblast morphology (Figure 3) . Histologically, all tumors were diuse liposarcomas composed of medium to large cells with round nuclei and were very similar to human liposarcomas (see http://www-medlib.med.utah.edu/WebPath/NEO-HTML/NEOPLO52.html) and liposarcomas generated in FUS ± CHOP transgenic mice (PeÂ rez-Losada et al., 2000a) . Similarly to FUS ± CHOP transgenic mice, the histopathological analyses of the white adipose depots in the double-transgenic FUSxCHOP animals revealed multiple abnormalities. Some contained only modest morphological changes consisting primarily of an increase in nuclear size and number per microscopic ®eld, but the white adipose tissue (WAT) of a majority of the mice had a much more hypercellular appearance and contained scattered cells with enlarged pleomorphic nuclei (Figure 3) . Nests of compact anaplastic liposarcoma cells were often scattered throughout the WAT depots. Similarly to FUS ± CHOP transgenic mice, WAT deposits in these animals were generally aected at least with abnormal adipocytes and, in some cases, foci of sarcomas were clearly discernible. Pathological changes were not observed in the brown adipose tissue (BAT) of these transgenic mice. Tumor in®ltration of non-adipose tissues was usually visible and was con®rmed microscopically (Figure 4 ). These data de®ne the tumors generated in the doubletransgenic FUSxCHOP as malignant liposarcomas. We next examined the expression of adipocyte-speci®c genes in order to de®ne the level at which the dierentiation is blocked in FUSxCHOP liposarcomas. Similarly to FUS ± CHOP transgenic mice (PeÂ rezLosada et al., 2000a) and despite their block in dierentiation each liposarcoma examined was found to express signi®cant levels of PPAR-g RNA, c/EBPb, d and a and aP2 comparable to that of normal fat and FUS ± CHOP liposarcomas (data not shown). These results suggest that liposarcomas in the doubletransgenic FUSxCHOP mice have been transformed at a point in the dierentiation process after induction of PPARg expression. Moreover, PPARg is not The human FUS cDNA containing a tag-sequence for the human c-Myc (amino acids 408 ± 439) at the 3' end was cloned into the pEF ± BOS vector, which contains the EF-1 promoter sequences and polyadenylation and splice signals from the human G-CSF gene, to give pEF ± FUS. (c) Expression of the pEF ± FUS transgene and expression of FUS and CHOP proteins in double FUSxCHOP transgenic mice was determined by Western blot analysis in the fat of a 2-month-old EF ± FUS and double FUSxCHOP transgenic, respectively. As a negative control we used the fat from a 2-month-old CHOP transgenic littermate. The location of FUS and CHOP is as indicated expressed in any other type of soft tissue sarcoma (Tontonoz et al., 1997) and can be considered a sensitive marker for distinguishing liposarcoma from other histologic types of soft tissue sarcoma. Therefore, the double-transgenic FUSxCHOP mice reproduce the same phenotype with which the FUS ± CHOP fusion gene is associated both in human pathology and transgenic mice (PeÂ rez-Losada et al., 2000a). These observations provide genetic evidence that FUS and CHOP domains function in trans for the mutual restoration of liposarcoma.
Embryonic fibroblasts from FUS mice differentiate into adipocytes but adipocyte differentiation is blocked in embryonic fibroblasts from double-transgenic FUSxCHOP mice
To investigate whether the FUS domain could restore the same adipocyte inhibition capacity than FUS ± CHOP in CHOP-expressing cells, we prepared primary embryonic ®broblasts from FUS and double-transgenic FUSxCHOP mice and examined their dierentiation properties as previously described (PeÂ rezLosada et al., 2000a). The embryonic ®broblasts from each line were cultured to con¯uent and then treated with the standard dierentiation induction medium. As shown in Figure 5 , embryonic ®broblasts from FUS and CHOP mice dierentiated into adipocytes and accumulated many lipid droplets in response to hormonal stimulants. In contrast, embryonic ®bro-blasts from double-transgenic FUSxCHOP mice can hardly dierentiate into adipogenic cells and accumulate very few lipid droplets, similarly to FUS ± CHOP embryonic ®broblasts ( Figure 5 ). The Oil-Red-O staining demonstrated clear dierences in adipocyte phenotype ( Figure 5 ) and, similarly to FUS ± CHOP MEFs, MEFs from double-transgenic FUSxCHOP mice only expressed the earliest markers of dierentiation (data not shown), which corresponds to preadipocytes. These results show that adipocyte dierentiation was blocked in cultured embryonic ®broblasts from double-transgenic FUSxCHOP mice but not in MEFs derived from CHOP transgenic mice treated with adipogenic hormons. Interference with the normal process of dierentiation contributes to the oncogenic potential of FUS ± CHOP fusion protein (PeÂ rez-Losada et al., 2000a) and this capacity is restored by the FUS domain into CHOP-expressing cells. , 2000b) . Concordant with these data, adipocyte dierentiation was not blocked in cultured CHOP embryonic ®broblasts treated with adipogenic hormones. Thus, these results show that the transcriptional activation by FUS is indispensable for tumorigenesis. However, these results do not clarify whether the relationship between the FUS and CHOP domains is in cis or in trans. To test the signi®cance of FUS and CHOP domain interactions within a living mouse, we generated mice expressing the FUS domain and crossed them with CHOPtransgenic mice to generate double-transgenic FUSx-CHOP animals. Here we show that expression of the FUS domain restores liposarcoma development in CHOP-transgenic mice. Double-transgenic FUSx-CHOP animals resulted in most of the symptoms of human liposarcomas, including the presence of lipoblasts with round nuclei, accumulation of intracellular lipid, induction of adipocyte-speci®c genes and a concordant block in the dierentiation program. No tumors of other tissues were found in these transgenic mice despite widespread activity of the EF1a promoter, underscoring the relevance of relationship between FUS-CHOP and the cell environment (SaÂ nchez-GarcõÂ a, 1997). Our results provide genetic evidence that FUS and CHOP domains function in trans for the mutual restoration of liposarcoma and support a model whereby the FUS ± CHOP fusion gene represents a gain-of-function mutation of both FUS and CHOP that deregulate both gene expression and protein activity. Further studies to identify the target genes and proteins that are regulated by FUS ± CHOP using our transgenic mice will produce a clearer picture of the development defect in liposarcoma. In conclusion, our results identify a new molecular mechanism responsible for the genesis of solid tumor-associated fusion genes which might have impact beyond myxoid liposarcoma.
Material and methods
The generation and screening of transgenic mice PCR ampli®cation of the FUS portion of FUS ± CHOP was done to facilitate cloning by adding restriction enzymes using primers that hybridize to the 5' and 3' ends of the FUS cDNA. The product was cloned into the M13mp19 vector, added to 3' end an in-frame sequence coding for a MYC-tag recognized for the 9E10 antibody, and sequenced. The cDNA was cloned into a plasmid, pEF ± BOS, containing sequences of the EF1-a promoter, followed by a polylinker region linked to the poly(A) adenylation signal from human G-CSF cDNA as described (Mizushima and Nagata, 1990) . Linear DNA fragments for microinjection were obtained by HindIII digestion and injected by the INIA Transgenic Facility into CBAxC57BL/6J fertilized eggs. Transgenic founders were identi®ed by Southern-blot analysis through detection of the novel EF-FUS construct from samples of DNA extracted from tails, respectively. CHOP mice has been previously described (PeÂ rez-Losada et al., 2000b) and double-transgenic FUSxCHOP animals were generated by crossing FUS and CHOP transgenic mice.
Histological analysis
FUS and double-transgenic FUSxCHOP mice were subjected to standard necropsy. All major organs were closely examined under the dissecting microscope, and samples of each organ were processed into paran, sectioned and examined histologically. Tumor specimens from the transgenic mice were ®xed into 10% formalin overnight, then Figure 5 Adipogenic dierentiation from primary embryonic ®broblasts expressing altered forms of FUS ± CHOP protein. Primary embryonic ®broblasts from each transgenic line were cultured in the presence of standard dierentiation induction medium (containing 0.5 mM isobutylmethylxantine, 1 mM dexamethasone, 5 mg/ml insulin and 10% FBS). After 8 days of dierentiation, cells were observed by light microscopy with Oil-Red-O staining. Cells from FUS, CHOP and double-transgenic FUSxCHOP mice are shown. The original magni®cation is 620. This experiment was repeated three times using cells prepared from all transgenic lines and from dierent embryos and similar results were obtained processed, embedded in paran, and 6 mm sections were stained with hematoxylin and eosin and photographed. All tissue samples were taken from homogenous and viable portions of the resected sample by the pathologist (T. Fores) and ®x within 2 ± 5 min of excision.
Preparation of primary embryonic fibroblasts and induction of adipogenic differentiation
Primary embryonic ®broblasts were harvested from 14.5 d.p.c. embryos. Cells were cultured at 378C in Dulbecco's modi®ed Eagle's medium (DMEM; Boehringer Ingelheim) supplemented with 10% heat-inactivated FBS (GIBCO/ BRL). Cells were plated to 24-well or 60 mm plastic dishes and propagated to con¯uence. Two days later, medium was replaced with standard dierentiation induction medium containing 0.5 mM isobutylmethylxantine (Sigma), 1 mM dexamethasone (Sigma), 5 mg/ml insulin (Sigma) and 10% FBS (GIBCO/BRL). This medium was removed every other day. After 8 days, the appearance of cytoplasmic lipid accumulation was observed by microscopy with Oil-Red-O staining. The Oil-Red-O staining was performed as follows: cells were washed with phosphate-buered saline (PBS), and then stained with 60% ®ltered Oil-Red-O stock solution (0.15 g of Oil-Red-O (Sigma) in 50 ml of isopropanol) for 30 min at 378C. Cells were washed ®rst with 60% isopropanol and then brie¯y with water and visualized.
Western blot analysis
Single cell suspensions coming from dierent tissue samples were analysed by immunoblotting procedures essentially as described (Castellanos et al., 1997) . Lysates were run on a 10% SDS ± PAGE gel and transferred to a PVDF membrane. After blocking, the membrane was probed with c-Myc (9E10) mouse monoclonal antibody (Santa Cruz), which is speci®c for human c-Myc (amino acids 408 ± 439). Reactive bands were detected with an ECL system (Amersham).
